UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of Principal Executive Offices) (Zip Code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class: |
Trading |
Name of each exchange | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. | Other Events. |
XOMA US LLC, a wholly owned subsidiary of XOMA Corporation (the “Company”), continues to maintain its July 1, 2008, Amended and Restated Research, Development and Commercialization Agreement with collaboration partner Novartis for iscalimab. On August 27th 2021, Novartis shared with the Company that based upon preliminary interim analysis results of Novartis’ Phase 2b kidney transplant study with iscalimab (CIRRUS I), Novartis intended to discontinue the study. According to Novartis, the study would be discontinued due to iscalimab-based treatment being less efficacious than tacrolimus-based treatment in prevention of organ rejection in patients receiving a kidney transplant. At the same time Novartis also confirmed it is continuing all other iscalimab studies in indications other than kidney transplant, for example Sjögren’s Syndrome and Lupus Nephritis.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
XOMA CORPORATION | ||||||
Date: September 2, 2021 | By: | /s/ Thomas Burns | ||||
Thomas Burns | ||||||
Senior Vice President, Finance and Chief Financial Officer |